Elanco Animal Health Incorporated (ELAN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Greenfield, IN, United States. Der aktuelle CEO ist Jeffrey N. Simmons.
ELAN hat IPO-Datum 2018-09-20, 9,000 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $11.99B.
Elanco Animal Health Incorporated is a global animal health company that innovates, develops, manufactures, and markets pharmaceutical and nutritional products for both companion animals and farm animals. For pets, the company offers disease prevention products such as parasiticides and vaccines under brands including Seresto, Advantage, and Advantix, as well as therapeutic treatments for pain, osteoarthritis, and dermatological conditions. In the farm animal sector, Elanco provides vaccines, antibiotics, parasiticides, and nutritional health products for poultry, aquaculture, ruminant, and swine production, with key brands including Rumensin and Baytril. The company distributes its products through veterinarians, third-party distributors, and direct relationships with farm animal producers. Founded in 1954 and headquartered in Greenfield, Indiana, Elanco serves a diverse customer base spanning veterinary clinics and agricultural operations worldwide.
